Business Daily.
.
A+ R A-

imageTHOUSAND OAKS, Calif., Sept. 28, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 ASPECCT ('763) trial comparing Vectibix® (panitumumab) to Erbitux® (cetuximab) for the treatment of wild-type KRAS metastatic colorectal cancer in......


Page 1343 of 1908

Business Daily Media